Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced on December 1, 2025 that it granted a total of 23,284 restricted stock units (RSUs) to two newly hired employees as inducement awards under the company’s 2024 Inducement Stock Incentive Plan.

The RSUs vest in four equal installments on each one-year anniversary of the grant date through the fourth anniversary, and vesting is subject to the employees' continued service. The awards were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 23,284 restricted stock units (“RSUs”) to two newly hired employees.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

What did Solid Biosciences (SLDB) announce on December 1, 2025 about employee equity?

The company granted 23,284 RSUs to two newly hired employees as inducement awards under its 2024 Inducement Stock Incentive Plan.

How do the RSUs granted by SLDB vest and what is the timeline?

The RSUs vest in four equal annual installments, on each one-year anniversary of the grant date through year four, subject to continued service.

Under which plan and Nasdaq rule were the Solid Biosciences RSUs granted?

The grants were made under the 2024 Inducement Stock Incentive Plan as inducements consistent with Nasdaq Listing Rule 5635(c)(4).

How many employees received RSUs in the Solid Biosciences December 1, 2025 grant?

Two newly hired employees received the total award of 23,284 RSUs.

Are the RSU awards from SLDB conditional or guaranteed?

Vesting of the RSUs is conditional on each employee's continued service with the company through each vesting date.